1. Medtech Insight
  2. >>Business
  3. >>Strategy

Spotlight on Cardiovascular VC Funding In 1st Half 2006

Atrial fibrillation is the hottest sector among five highly dynamic areas within cardiovascular technology, according to an analysis by cvPipeline.

Atrial fibrillation (afib) is the hottest sector among five highly dynamic areas within cardiovascular technology, according to an analysis by cvPipeline of venture capital (VC) funding patterns in afib, heart failure, heart valves, regenerative medicine, and drug-eluting stents (DES) over the last year and a half.

The cvPipeline analysis shows that in the first half of 2006, eight afib start-ups received VC investments, and by contrast, during the first half of 2005, only one atrial fibrillation startup received funding. Among the largest recipients of VC funding during the first half of this year were CARDIOOPTICS (Wilmington, MA), which is developing a vision-guided radiofrequency catheter ablation system and raised $26.5 million in a Series B round; ATRITECH (Plymouth, MN), which is in a U.S. pivotal trial with the WATCHMAN left atrial appendage closure device and raised $22

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By Shubham Singh

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

China Still ‘Attractive’ For Danaher Despite $50M VBP Drag

 
• By Shubham Singh

Apart from the reimbursement-driven turbulence in diagnostics, other aspects of Danaher’s China business are showing signs of resilience. Patient volumes remain strong and the company does not see evidence that the Chinese government is attempting to actively push Western suppliers out of its healthcare system.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 
• By Natasha Barrow

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

More from Business

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Disparities — Including Financials Shortcomings — Remain In Women’s Health, Execs Say

 
• By Brian Bossetta

FemTech leaders discussed some of the barriers that remain in unlocking the full potential of the women’s health market during SiS New York last week. They also offered solutions.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.